Review
Biochemistry & Molecular Biology
Simone Feurstein, Michael Drazer, Lucy A. Godley
Summary: The advent of next-generation sequencing has revealed numerous germline predisposition disorders associated with hematopoietic malignancies, which are now recognized to be more common than previously thought. Challenges to accurate clinical testing include lack of standardization and familiarity, impacting clinical management and health surveillance strategies.
HUMAN MOLECULAR GENETICS
(2021)
Review
Oncology
Lucy A. A. Godley
Summary: Germline predisposition to hematopoietic malignancies is more common than previously recognized, and tumor-based profiling can help identify germline variants. Early germline genetic testing allows for appropriate treatment planning, and healthcare providers need to understand the differences between tumor-based profiling and germline genetic testing to interpret testing data comprehensively.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Georgina Gener-Ricos, Yoheved S. Gerstein, Danielle Hammond, Courtney D. DiNardo
Summary: Understanding the biological features and main clinical manifestations of hereditary hematologic malignancies is crucial for identifying and referring patients with myelodysplastic syndrome who may have an inherited predisposition. Individualized genetic counseling and informed treatment decisions, particularly regarding donor selection for hematopoietic stem cell transplant, are important. Future research will enhance our understanding of these disorders and improve management of affected patients and their families.
Article
Oncology
Arianna Dal Buono, Laura Poliani, Luana Greco, Paolo Bianchi, Monica Barile, Valentina Giatti, Cristiana Bonifacio, Silvia Carrara, Alberto Malesci, Luigi Laghi
Summary: This study investigated the prevalence of germline mutations in cancer predisposition genes in patients with pancreatic ductal adenocarcinoma (PDAC) or suspected related hereditary syndromes. The results showed that 20.1% of the tested subjects carried at least one pathogenic variant in the genes of interest. Therefore, the incorporation of genetic testing and multiple-gene panels in the management of pancreatic cancer would be beneficial.
Article
Hematology
Emma St Martin, Alejandro Ferrer, Abhishek A. Mangaonkar, Shakila P. Khan, Mira A. Kohorst, Avni Y. Joshi, William J. Hogan, Horatiu Olteanu, Ann M. Moyer, Aref Al-Kali, Ayalew Tefferi, Dong Chen, Kitsada Wudhikarn, Ronald Go, David Viswanatha, Rong He, Rhett Ketterling, Phuong L. Nguyen, Jennifer L. Oliveira, Naseema Gangat, Terra Lasho, Mrinal M. Patnaik
Summary: Germline predisposition syndromes (GPS) are caused by constitutional abnormalities in tumor suppressive and homeostatic genes, leading to an increased risk of neoplasia in affected individuals. This study presented clinical and genomic data on 144 Mayo Clinic patients with GPS, revealing distinct patterns in different subtypes of GPS and the importance of comprehensive management approaches for patients with hematological neoplasms.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Genetics & Heredity
Deborah F. Nacer, Johan Vallon-Christersson, Nicklas Nordborg, Hans Ehrencrona, Anders Kvist, Ake Borg, Johan Staaf
Summary: The study found that breast tumors in patients screened for PGVs showed more aggressive characteristics, especially in the case of triple-negative breast cancer (TNBC). However, the ability to improve screening accuracy using current patient and tumor characteristics remains questionable and further research is needed.
Review
Oncology
Serine Avagyan, Akiko Shimamura
Summary: Pediatric myelodysplastic syndromes (MDS) may be caused by a germline predisposition, but patients may lack syndromic features. Germline predisposition can be associated with genetic mutations found in de novo MDS and leukemias, highlighting the need to distinguish their origin. Confirming a diagnosis of germline predisposition is crucial for treatment, monitoring, and family counseling. Germline predisposition can occur at any age and the risk of MDS may increase with age. Increasing awareness in adult patients can improve medical management and provide opportunities for prevention or interception of malignancy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Pia Michler, Anne Schedel, Martha Witschas, Ulrike Anne Friedrich, Rabea Wagener, Juha Mehtonen, Triantafyllia Brozou, Maria Menzel, Carolin Walter, Dalileh Nabi, Glen Pearce, Miriam Erlacher, Gudrun Goehring, Martin Dugas, Merja Heinaeniemi, Arndt Borkhardt, Friedrich Stoelzel, Julia Hauer, Franziska Auer
Summary: This study identified a novel germline stop-gain variant in the shelterin complex gene POT1 in a child with acute myeloid leukemia, which resulted in increased DNA damage and chromosomal instabilities. The variant also led to telomeric elongation and highlighted the predisposition to myeloid malignancies in childhood caused by POT1 germline deficiency.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Himachandana Atluri, Yoheved S. Gerstein, Courtney D. DiNardo
Summary: With the use of next generation sequencing (NGS), several genes have been identified that carry a risk of inheriting hematologic malignancies. Identification of individuals with hereditary hematologic malignancies (HHM) involves attention to family history, clinical features, and variant allele frequency on somatic NGS panels. Genetic counseling is critical for optimizing diagnostic testing and treatment strategies.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
(2022)
Article
Oncology
Daijing Nie, Jing Zhang, Fang Wang, Xvxin Li, Lili Liu, Wei Zhang, Panxiang Cao, Xue Chen, Yang Zhang, Jiaqi Chen, Xiaoli Ma, Xiaosu Zhou, Qisheng Wu, Ming Liu, Mingyue Liu, Wenjun Tian, Hongxing Liu
Summary: The study suggests that heterozygous mutations in Fanconi anemia genes can contribute to hematologic disorders, particularly aplastic anemia and leukemia. Different genes have varying frequencies of mutations, with some genes showing associations with specific subgroups of hematologic malignancies.
FRONTIERS OF MEDICINE
(2022)
Article
Urology & Nephrology
Patrick T. Gomella, James Ryan Mark, Veda N. Giri, William Kevin Kelly, Leonard G. Gomella
Summary: In the expanding field of precision medicine, the use of genetics in the evaluation and treatment of patients with urologic cancers associated with inherited genetic mutations has significantly increased. Familiarity with current guidelines for germline testing is important for impacting screening and treatment decisions.
EUROPEAN UROLOGY FOCUS
(2022)
Article
Oncology
Wei Yuan, Zhen Shang, Kefeng Shen, Qiuxia Yu, Qiuxia Lv, Yang Cao, Jue Wang, Yi Yang
Summary: This article reports a case of familial leukemia and identifies 8 shared germline gene mutations related to leukemia. A novel possible leukemia-related germline gene variant is discovered, which provides a new understanding for the screening and pathogenesis of hereditary predisposition syndromes.
FRONTIERS IN ONCOLOGY
(2023)
Review
Cell Biology
Khaleel Al-Obaidy, Zainab Alruwaii, Sean R. Williamson, Liang Cheng
Summary: This review provides an overview of the current understanding, clinical and pathological presentations, molecular pathogenesis, advances in therapeutic implications, and targeted therapy of genetic renal neoplasia syndromes.
Article
Oncology
Pablo Gargallo, Silvestre Oltra, Yania Yanez, Antonio Juan-Ribelles, Ines Calabria, Vanessa Segura, Marian Lazaro, Julia Balaguer, Teresa Tormo, Sandra Dolz, Jose Maria Fernandez, Carolina Fuentes, Barbara Torres, Mara Andres, Maria Tasso, Victoria Castel, Jaime Font de Mora, Adela Canete
Summary: The project aims to offer genetic germline analysis to all pediatric cancer patients in order to identify predisposing genetic variants and explore new genotype-phenotype relationships. The study found a significant incidence of predisposing genetic alterations in pediatric cancer patients and highlights the need for expert genetic counseling in identifying such variants. The results confirm the importance of ongoing research on genetic predisposition in pediatric oncology and the utility of genetic screening tools for early detection and management.
Article
Oncology
K. Pauley, C. Koptiuch, S. Greenberg, W. Kohlmann, J. Jeter, S. Colonna, T. Werner, C. Kinsey, G. Gilcrease, J. Weis, J. Whisenant, V Florou, I Garrido-Laguna
Summary: This study evaluated discrepancies between tumor genomic profiling and germline genetic testing, and found that unrecognized germline pathogenic variants may harm patients by missing hereditary syndromes and targeted therapy opportunities. The findings highlight the importance of comprehensive germline assessment and referring patients for genetic evaluation regardless of somatic testing outcomes.